Ionis Pharmaceuticals Stock Fair Value – IONIS PHARMACEUTICALS Reports 40.5% Year-over-Year Revenue Increase in Second Quarter of FY2023
August 13, 2023
☀️Earnings Overview
For the second quarter of FY2023, which ended on June 30, 2023, IONIS PHARMACEUTICALS ($NASDAQ:IONS) reported total revenue of USD 188.0 million – representing a 40.5% year-over-year increase. Net income decreased by 19.1% year-over-year, amounting to USD -85.0 million.
Analysis – Ionis Pharmaceuticals Stock Fair Value
GoodWhale’s analysis of IONIS PHARMACEUTICALS‘s wellbeing has determined that the intrinsic value of its shares is around $28.6, a figure calculated using our proprietary Valuation Line. Despite this, the stock is currently being traded at a price of $40.0, rendering it significantly overvalued by 39.9%. This indicates that there is potential for investors to make a profit if they act soon enough. Additionally, this could be an indication that the company is undervalued compared to its current market capitalization. As such, investors should consider whether this is an opportunity to buy before the stock prices return to a more reasonable level. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Ionis Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 630.59 | -309.04 | -69.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ionis Pharmaceuticals. More…
| Operations | Investing | Financing |
| -455.98 | -227.91 | 586.44 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ionis Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.97k | 2.54k | 2.99 |
Key Ratios Snapshot
Some of the financial key ratios for Ionis Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -12.5% | – | -39.0% |
| FCF Margin | ROE | ROA |
| -78.2% | -33.6% | -5.2% |
Peers
The company has a strong focus on developing treatments for rare diseases. Alnylam Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, and Nyrada Inc are all companies that also specialize in the development of drugs that target RNA.
– Alnylam Pharmaceuticals Inc ($NASDAQ:ALNY)
Alnylam Pharmaceuticals Inc is a Massachusetts-based biopharmaceutical company that focuses on the discovery and development of RNA interference therapeutics. As of January 2021, the company had a market capitalization of $25.21 billion and a return on equity of -1173.18%. The company’s products are in various stages of development and include treatments for genetic disorders, infectious diseases, and cancer.
– Rigel Pharmaceuticals Inc ($NASDAQ:RIGL)
Rigel Pharmaceuticals Inc is a publicly traded company that focuses on the development of drugs for the treatment of autoimmune and inflammatory diseases, cancer, and other conditions. As of 2022, the company had a market capitalization of 127.9 million and a return on equity of 418.83%. Rigel’s products include Tavalisse, a treatment for chronic immune thrombocytopenic purpura, and fostamatinib, a treatment for autoimmune and inflammatory diseases. The company is headquartered in South San Francisco, California.
– Nyrada Inc ($ASX:NYR)
Nyrada Inc is a clinical-stage biopharmaceutical company focused on the development of first-in-class therapeutic drugs to treat diseases of the eye, central nervous system and endocrine system. The company’s lead product candidate, NYX-2925, is in clinical development for the treatment of glaucoma and other eye diseases. As of 2022, Nyrada Inc had a market cap of 21.06M and a Return on Equity of -20.85%. The company’s focus on developing first-in-class drugs to treat various diseases makes it an attractive investment for those looking to invest in the healthcare sector.
Summary
IONIS PHARMACEUTICALS reported strong financials for Q2 of FY2023, with total revenue of USD 188.0 million – a 40.5% year-over-year increase. Net income however was USD -85.0 million, a 19.1% decrease compared to the previous year’s Q2. Investors should note that IONIS PHARMACEUTICALS is still a young company with plenty of potential for future growth, as evidenced by the consistent year-over-year revenue growth. However, the current net loss is a cause for concern and investors will want to monitor the company’s future performance closely.
Related Posts
Recent Posts
